TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36093738
Drug: Elezanumab 50-1,600mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elezanumab 50-1,600mg IV and 150mg subcutaneous
Study: 36094733
Drug: Follicular group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follicular group (mean serum MOR levels: 275 ± 32 pg/ml)
Study: 36094733
Drug: Luteal group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luteal group (mean serum MOR levels: 254 ± 28 pg/ml)
Study: 36094804
Drug: Constant Therapy
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant Therapy (tablet-based training)
Study: 36094839
Drug: Cemiplimab (350
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cemiplimab (350 mg every 3 weeks for up to four doses)
Study: 36095841
Drug: Itacitinib 200
Normalized name: itacitinib
DrugBank: Itacitinib (DB12154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itacitinib 200 mg/d for 28 days
Study: 36095841
Drug: SCS treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCS treatment
Study: 36095849
Drug: Cilta-cel infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cilta-cel infusion after lymphodepletion
Study: 36096442
Drug: Brigatinib 180
Normalized name: brigatinib 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brigatinib 180 mg once daily (after 7-day 90-mg lead-in)
Study: 36096442
Drug: Brigatinib 180
Normalized name: brigatinib 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brigatinib 180 mg once daily (after 7-day 90-mg lead-in) in patients with ctDNA-detectable baseline ALK fusion (n=64)
Study: 36096442
Drug: Brigatinib 180
Normalized name: brigatinib 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brigatinib 180 mg once daily (after 7-day 90-mg lead-in) in patients who progressed on alectinib (n=86)
Study: 36096532
Drug: BND-22 (ILT2-blocking
Approvals — FDA: no, EMA: no, PMDA: no
Description: BND-22 (ILT2-blocking antibody)
Study: 36096940
Drug: Group Metacognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Metacognitive Therapy (MCT), up to eight sessions delivered by a CAMHS mental health practitioner
Study: 36096940
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care in CAMHS (individual or group-based therapy)
Study: 36097216
Drug: neoadjuvant atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: neoadjuvant atezolizumab monotherapy
Study: 36097345
Drug: GSK1795091 (modified
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1795091 (modified formulation)
Study: 36097345
Drug: GSK1795091 (original
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1795091 (original formulation)
Study: 36097345
Drug: GSK1795091 (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1795091 (both formulations)
Study: 36097602
Drug: Asfotase alfa
Normalized name: Asfotase alfa
DrugBank: Asfotase alfa (DB09105)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Asfotase alfa (enzyme replacement therapy)
Study: 36097844
Drug: BNT162b2 mRNA
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 Injectable Suspension [Comirnaty]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b2 mRNA vaccine (fourth dose)
Study: 36098320
Drug: Nivolumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab plus ipilimumab (nivolumab 240 mg every 2 weeks and ipilimumab 1 mg/kg every 6 weeks)
Study: 36098320
Drug: Nivolumab alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab alone (240 mg every 2 weeks)
Study: 36099010
Drug: Single-patch 12-lead
Normalized name: lead
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-patch 12-lead ECG (SP-ECG)
Study: 36100318
Drug: Cocoa (dark
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocoa (dark chocolate) 30 g/day for 1 week
Study: 36100355
Drug: Intranasal nalbuphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal nalbuphine (0.1 mg/kg)
Study: 36100355
Drug: Intravenous nalbuphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nalbuphine (0.05 mg/kg)
Study: 36100698
Drug: Steroid quantitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid quantitation
Study: 36101520
Drug: ROS1-selective inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ROS1-selective inhibitors
Study: 36101656
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) 10 mg orally
Study: 36103643
Drug: MTB-directed therapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTB-directed therapy (both on-label and off-label therapies)
Study: 36103643
Drug: MTB-directed therapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTB-directed therapy
Study: 36104359
Drug: camrelizumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: camrelizumab (200 mg, q2w) and apatinib (250 mg, once daily)
Study: 36104795
Drug: Elraglusib (9-ING-41)
Normalized name: Elraglusib
DrugBank: Elraglusib (DB16047)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elraglusib (9-ING-41) as a single agent
Study: 36104795
Drug: Elraglusib (9-ING-41)
Normalized name: Elraglusib
DrugBank: Elraglusib (DB16047)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elraglusib (9-ING-41) in combination with anti-PD-1 mAb
Study: 36104795
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy with elraglusib and anti-PD-1 mAb
Study: 36105230
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine intervention
Study: 36105914
Drug: Ruxolitinib at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib at the maximum safe starting dose (MSSD) of 10 mg bid
Study: 36105925
Drug: Remotely controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remotely controlled mandibular positioner (RCMP) titration during in-lab sleep study
Study: 36107220
Drug: Famitinib 25
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Famitinib 25 mg
Study: 36107221
Drug: BCMA-CART cell
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCMA-CART cell therapy
Study: 36107363
Drug: Prophylactic beta-blockers
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic beta-blockers
Study: 36107394
Drug: Zandelisib (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zandelisib (45 or 60 mg daily)
Study: 36107483
Drug: Systemic treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic treatment based on genetic analyses of tumor tissue
Study: 36108256
Drug: In-home rapid
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-home rapid antigen COVID-19 testing (BinaxNOW), administered twice weekly for three months.
Study: 36108259
Drug: Dual HER2-targeted
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dual HER2-targeted therapy (trastuzumab plus pertuzumab)
Study: 36108259
Drug: Standard-of-care neoadjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care neoadjuvant chemotherapy with trastuzumab
Study: 36108304
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) JZP458 25/25/50 mg/m2 MWF
Study: 36108304
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) JZP458 25 mg/m2 MWF
Study: 36108304
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) JZP458 37.5 mg/m2 MWF
Study: 36108308
Drug: Rondaptivon pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rondaptivon pegol (3 mg on days 0 and 4, then weekly doses of 2 to 9 mg until day 28)
Study: 36108308
Drug: Rondaptivon pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rondaptivon pegol (6 doses)
Study: 36108661
Drug: Selpercatinib (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selpercatinib (160 mg twice daily)
Study: 36109029
Drug: Digital exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital exposure treatment
Study: 36109430
Drug: Immediate drug
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate drug withdrawal after delivery
Study: 36109430
Drug: Delayed drug
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed drug withdrawal at 6 weeks after delivery
Study: 36109652
Drug: Microencapsulated watermelon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microencapsulated watermelon rind (MWR) 30 g containing 4 g of L-citrulline
Study: 36110277
Drug: Integrative medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative medicine (acupuncture, Chinese herbs, repeated transcranial magnetic stimulation)
Study: 36110277
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (basic treatment, general nursing care, exercise therapy)
Study: 36110295
Drug: Intermittent PEG-IFNα
Normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent PEG-IFNα therapy
Study: 36110295
Drug: Initial treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial treatment HBsAg response
Study: 36110959
Drug: E150 (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: E150 (150 mg erlotinib for non-smokers)
Study: 36110959
Drug: E300 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: E300 (300 mg erlotinib for smokers)
Study: 36110959
Drug: Early in-treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early in-treatment [18]FDG PET/CT
Study: 36111288
Drug: Oral antipsychotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antipsychotic (OAP) treatment
Study: 36111839
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy initiated with a delay (≥8 weeks after surgical resection)
Study: 36111839
Drug: Timely initiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timely initiation of adjuvant chemotherapy
Study: 36113242
Drug: FCN-159 (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: FCN-159 (12 mg QD)
Study: 36113242
Drug: FCN-159 (≥6
Approvals — FDA: no, EMA: no, PMDA: no
Description: FCN-159 (≥6 mg QD)
Study: 36113895
Drug: Talimogene laherparepvec
Normalized name: Talimogene laherparepvec
DrugBank: Talimogene laherparepvec (DB13896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Talimogene laherparepvec (T-VEC) followed by intratumoral injection of CD1c (BDCA-1)
Study: 36113946
Drug: Structural harm
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structural harm reduction strategies (e.g., syringe service programmes)
Study: 36113962
Drug: Mycophenolic acid
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mycophenolic acid (MPA) treatment
Study: 36113962
Drug: MPA treatment
Normalized name: polyurethane-34 (55 MPA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPA treatment (adjusted analysis)
Study: 36114102
Drug: dupilumab 300
Normalized name: dupilumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: dupilumab 300 mg every 2 weeks up to 96 weeks
Study: 36115673
Drug: Neoadjuvant SBRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant SBRT (8 Gy × 3 fractions) plus PD-1 inhibitor (tislelizumab) administered in two cycles with a 3-week interval before surgery.
Study: 36115674
Drug: REVEAL(OT) intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: REVEAL(OT) intervention added to standard multidisciplinary chronic pain treatment
Study: 36115931
Drug: Anti-PD-1 combination
Normalized name: Dianeal PD-2/1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-PD-1 combination therapy
Study: 36115947
Drug: erenumab 70-140
Normalized name: erenumab-aooe 140 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: erenumab 70-140 mg s.c. every 28 days for one year
Study: 36115980
Drug: Simvastatin, L-arginine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin, L-arginine, and tetrahydrobiopterin
Study: 36116169
Drug: Anlotinib combined
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib combined with platinum-etoposide (chemotherapy)
Study: 36116288
Drug: Norepinephrine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine administration during PLR
Study: 36116293
Drug: remedē System
Approvals — FDA: no, EMA: no, PMDA: no
Description: remedē System Therapy (transvenous phrenic nerve stimulation)
Study: 36116506
Drug: Anti-CEL IgG
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-CEL IgG and IgA antibodies in patients with HS
Study: 36116866
Drug: Abundant microaspiration
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Abundant microaspiration (positive pepsin A ≥ 6.25 ng/mL)
Study: 36117003
Drug: mRNA COVID-19
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA COVID-19 vaccines (BNT162b2 and mRNA-1273)
Study: 37031282
Drug: mRNA COVID-19
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA COVID-19 vaccines
Study: 36117166
Drug: Post-direct-acting antiviral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-direct-acting antiviral agent HCC
Study: 36117973
Drug: Low-dose dexmedetomidine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dexmedetomidine (0.1 to 0.2 μg/kg/h)
Study: 36118751
Drug: Sugar-sweetened soda
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar-sweetened soda (1 L/day)
Study: 36119522
Drug: mDCF (docetaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: mDCF (docetaxel 40 mg/m², cisplatin, and 5-fluorouracil) followed by chemoradiotherapy
Study: 36119641
Drug: cCRT (concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: cCRT (concurrent chemoradiotherapy)
Study: 36119641
Drug: EGFR-TKI monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGFR-TKI monotherapy
Study: 36119669
Drug: Botulinum neurotoxin
Normalized name: Botulinum neurotoxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum neurotoxin A (BoNT-A) treatment
Study: 36120090
Drug: BNT162b2 mRNA
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 Injectable Suspension [Comirnaty]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b2 mRNA vaccine (30 μg), administered in two doses intramuscularly, 21 days apart
Study: 36120713
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard outpatient treatment)
Study: 36120850
Drug: Salvage radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salvage radiation therapy (sRT) with or without 2 years of Bicalutamide
Study: 36121244
Drug: Pharmacomechanical catheter-directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacomechanical catheter-directed thrombolysis (PM-CDT) using the Bashir endovascular catheter with 7 mg tPA infused over 5 hours.
Study: 36121499
Drug: Enteric-coated aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated aspirin (EC-ASA)
Study: 36121499
Drug: Plain aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain aspirin (P-ASA)
Study: 36121707
Drug: ARP strategy
Normalized name: erythromycin stearate Oral Suspension [Arpimycin]
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARP strategy (LSM < 1.805 m/s or SSM < 2.445 m/s and PLT > 110 × 10^9/L)
Study: 36122888
Drug: Culprit drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culprit drug identification through combined skin testing, in vitro testing, or drug provocation tests.
Study: 36123069
Drug: Rapid serological
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid serological test targeting IgM and IgG against the receptor binding domain of SARS-CoV-2
Study: 36123169
Drug: Opioid vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid vaccines
Study: 36123697
Drug: TransCon TLR7/8
Approvals — FDA: no, EMA: no, PMDA: no
Description: TransCon TLR7/8 Agonist
Study: 36124180
Drug: HLX04-O intravitreal
Approvals — FDA: no, EMA: no, PMDA: no
Description: HLX04-O intravitreal injections at a dose of 1.25 mg/0.05 mL every four weeks
Study: 36124180
Drug: HLX04-O intravitreal
Approvals — FDA: no, EMA: no, PMDA: no
Description: HLX04-O intravitreal injections
Study: 36124767
Drug: Optimal Medical
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal Medical Treatment
Study: 36124872
Drug: Optimal medical
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal medical therapy at discharge
Study: 36124924
Drug: Talazoparib 1
Normalized name: talazoparib 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talazoparib 1 mg/day (0.75 mg/day for moderate renal impairment)
Study: 36125116
Drug: Brain-computer interface
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brain-computer interface (BCI) used to control a virtual hand, specific details on dosage and duration not available.
Study: 36125263
Drug: Durvalumab +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab + Metformin
Study: 36125356
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of qSOFA and IMX-SEV-2
Study: 36125356
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of IMX-SEV-2 and qSOFA
Study: 36126298
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive pill adherence
Study: 36126315
Drug: Compression therapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compression therapy, details on dosage and duration not available.
Study: 36127767
Drug: Pemigatinib 13.5
Normalized name: pemigatinib 13.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemigatinib 13.5 mg oral once daily (3-week cycle; 2 weeks on, 1 week off)
Study: 36129032
Drug: No oral
Normalized name: Beano Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No oral anticoagulants
Study: 36129273
Drug: Factor Xa
Normalized name: Anti factor Xa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Factor Xa inhibitor use
Study: 36129688
Drug: Apremilast, 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apremilast, 30 mg, twice daily
Study: 36129839
Drug: Preference for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preference for testing when offered hypothetical CHIP treatment
Study: 36129967
Drug: NJH395 (Anti-HER2-TLR7
Approvals — FDA: no, EMA: no, PMDA: no
Description: NJH395 (Anti-HER2-TLR7 Immune-Stimulator Antibody Conjugate)
Study: 36130137
Drug: Acupuncture treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment, details on dosage and duration not available.
Study: 36130401
Drug: CRP and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRP and IL-6 combination
Study: 36130693
Drug: Radiotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy with doses of 60 to 72 Gy in 2 Gy fractions
Study: 36131349
Drug: General floor
Approvals — FDA: no, EMA: no, PMDA: no
Description: General floor treatment
Study: 36131349
Drug: ICU treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICU treatment
Study: 36131934
Drug: CAR-T-cell therapy
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAR-T-cell therapy
Study: 36133827
Drug: Prescription opioid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription opioid misuse (POM)
Study: 36136180
Drug: Computer-guided buccal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-guided buccal cortical plate separation
Study: 36136294
Drug: Socazolimab (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Socazolimab (5 mg/kg)
Study: 36136377
Drug: Music Imagery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music Imagery (8-weekly, individual sessions)
Study: 36136794
Drug: Confidence in
Normalized name: miconazole nitrate Topical Cream [Clearly Confident]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Confidence in the treatment
Study: 36137526
Drug: MicroShunt implantation
Approvals — FDA: no, EMA: no, PMDA: no
Description: MicroShunt implantation with adjunctive use of mitomycin C (0.2-0.4 mg/mL applied for 2-3 min)
Study: 36137752
Drug: MICs infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MICs infusion before kidney transplantation
Study: 36137752
Drug: MICs infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MICs infusion (highest dose) 7 days before surgery
Study: 36137752
Drug: MICs infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MICs infusion (highest dose)
Study: 36137752
Drug: MICs infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MICs infusion
Study: 36138362
Drug: Chemotherapy without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy without immunotherapy
Study: 36139910
Drug: 10.5 g
Normalized name: Gelatin Capsules, 10.5 gr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10.5 g mixture of trehalose, spermidine, nicotinamide, and polyphenols
Study: 36143102
Drug: Vitamin-K antagonists
Normalized name: Vitamin K antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin-K antagonists (VKA)